Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $722
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst David Phung has maintained an Overweight rating on Eli Lilly (NYSE:LLY) and raised the price target from $673 to $722.
November 03, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Eli Lilly and raised the price target, which could lead to a positive market reaction.
The Overweight rating maintained by Morgan Stanley indicates a positive outlook for Eli Lilly. The increase in the price target from $673 to $722 suggests that the analyst sees further upside potential in the stock, which could lead to a positive market reaction in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100